Pediatrix Medical Group (MD) Stock Price, News & Analysis

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pediatrix Medical Group in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MD, but not buy additional shares or sell existing shares.
View MD analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1 year price objectives for Pediatrix Medical Group's shares. Their MD share price targets range from $9.00 to $14.00. On average, they expect the company's stock price to reach $10.30 in the next year. This suggests a possible upside of 14.1% from the stock's current price.
View analysts price targets for MD or view top-rated stocks among Wall Street analysts.

Pediatrix Medical Group's stock was trading at $9.30 at the start of the year. Since then, MD shares have decreased by 2.9% and is now trading at $9.03.
View the best growth stocks for 2024 here.

Pediatrix Medical Group saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,030,000 shares, an increase of 25.2% from the February 29th total of 3,220,000 shares. Based on an average daily volume of 732,700 shares, the short-interest ratio is currently 5.5 days. Currently, 4.9% of the shares of the stock are short sold.
View Pediatrix Medical Group's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our MD earnings forecast.

Pediatrix Medical Group, Inc. (NYSE:MD) posted its quarterly earnings data on Tuesday, February, 20th. The company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.02. The business earned $496.44 million during the quarter, compared to the consensus estimate of $524.30 million. Pediatrix Medical Group had a negative net margin of 3.03% and a positive trailing twelve-month return on equity of 10.35%. The firm's revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.46 earnings per share.

ETFs with the largest weight of Pediatrix Medical Group (NYSE:MD) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap 600 Pure Value ETF (RZV) and Syntax Stratified SmallCap ETF (SSLY).iShares U.S. Healthcare Providers ETF (IHF).

6 employees have rated Pediatrix Medical Group Chief Executive Officer Mark S. Ordan on Glassdoor.com. Mark S. Ordan has an approval rating of 34% among the company's employees. This puts Mark S. Ordan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pediatrix Medical Group investors own include NVIDIA (NVDA), AbbVie (ABBV), QUALCOMM (QCOM), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), Walt Disney (DIS), Wells Fargo & Company (WFC), Exxon Mobil (XOM) and Advanced Micro Devices (AMD).

Pediatrix Medical Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%). Insiders that own company stock include James D Swift, John C Pepia, Mark S Ordan, Mary Ann E Moore, Roger Mack Hinson, Roger Md Medel and Shirley A Weis.
View institutional ownership trends.

Shares of MD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.